The US Food and Drug Administration (FDA) has granted orphan drug designation to Shire’s investigational mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody, SHP647, for the treatment of paediatric patients with moderately to severely active ulcerative colitis (UC).

MAdCAM-1 plays a significant role in leukocyte trafficking in the person’s gastrointestinal (GI) tract and appears to allow excessive lymphocyte infiltration under conditions of chronic GI inflammation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Formerly known as PF-00547659, Shire’s SHP647 is a fully human IgG2 monoclonal antibody that directly targets the MAdCAM-1, and inhibits α4β7 integrin binding to human MAdCAM-1 with high affinity and selectivity.

The biopharmaceutical company is currently evaluating the therapy in Phase III studies for the treatment of moderately to severely active UC in adult patients.

“We’re pleased to receive orphan drug designation for SHP647, and we’re excited about our continued work to develop this compound.”

Shire’s plan to conduct paediatric study on SHP647 is currently under discussion with health authorities.

Shire Therapeutic Area Development GI, Endocrine and Metabolism lead Dr Debra Silberg said: “We’re pleased to receive orphan drug designation for SHP647, and we’re excited about our continued work to develop this compound.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“If approved, SHP647 holds the potential to help treat patients with UC. Shire’s study plans for SHP647 in the paediatric population align well with our commitment to address unmet patient need.”

In October this year, the company received orphan drug designation for its gene therapy candidate SHP654 (BAX 888) from the US FDA.

SHP654 is an investigational factor VIII (FVIII) gene therapy for the treatment of patients with haemophilia A.